2023 annual financial data

TScan Therapeutics 2023 Net margin

Direct answer

Net margin was -423.86%.

Operating income was -93.46M USD and net income was -89.22M USD.
Operating cash flow was -61.36M USD.

Get free TScan Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
21.05M USD
Operating income
-93.46M USD
Net income
-89.22M USD
Operating cash flow
-61.36M USD